Print
Email
Print Edition Stories
Thursday, January 22, 2009
Stromedix wins patents for its fibrosis-fighting compounds
Rodney Brown on NECN: Hacking into medical devices
Streaming Video: Mass High Tech All-Stars Thought Leadership Roundtable
In their own words: Tod Woolf, CEO, RXi Pharmaceuticals Corp.
Biotech company Stromedix Inc. has secured broad patent rights to a family of monoclonal antibodies, which will assist the company as it continues to develop its lead product, STX-100.
The Cambridge-based firm specializes in creating therapies for fibrosis and fibrotic organ failure. Fibrosis is caused by the body’s attempt to repair chronic tissue injury. Over a period of years, this process can leave scar tissue in affected organs and disrupt normal tissue functions and even cause organ failure.
This past week, Stromedix announced the U.S. Patent Office has granted it patents for its monoclonal antibodies technologies, including compositions related to its lead product, STX-100. The ST-100 technology targets a type of integrin (a key cell surface receptor) that is an important regulator of fibrosis and tissue injury. Stromedix expects this will offer it intellectual property protection for its relevant antibody-based therapeutics through at least 2023.
Stromedix recently completed the Phase 1 clinical trial for STX-100, a humanized monoclonal antibody exclusively licensed from Cambridge-based biotech Biogen Idec Inc. The compound has exhibited anti-fibrotic activity in preclinical animal models of kidney, lung, and liver disease.
In early 2009, Stromedix will initiate a Phase 2 trial in kidney transplant patients with interstitial fibrosis and tubular atrophy. In August, the U.S. Food and Drug Administration granted STX-100 orphan drug status as a treatment for chronic allograft nephropathy. This is a cause of transplant failure in kidney transplant patients; the condition currently has no FDA-approved treatment.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
